| Autor: |
Suk Bong Koh |
| Jazyk: |
angličtina |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
Kosin Medical Journal, Vol 33, Iss 3, Pp 283-288 (2018) |
| Druh dokumentu: |
article |
| ISSN: |
2005-9531 |
| DOI: |
10.7180/kmj.2018.33.3.283 |
| Popis: |
Historically, the standard treatment for early-stage cervical cancer has been radical surgery in patients with operable disease. Patients with locally advanced disease (defined as FIGO stage IB2 and usually with tumors greater than 4 cm, IIB, III and IVA) are usually treated with radical radiotherapy, which consists of external beam radiotherapy and internal brachytherapy. However, the discovery that cervical cancer tumors are sensitive to chemotherapy led to the initiation of studies looking at adding chemotherapy to both radiotherapy and surgery. Following a National Cancer Institute (NCI) alert in 1999 (NCI 1999), chemoradiotherapy became the standard of care for women with locally advanced cervical cancer.1 |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
